Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 20/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6217369 | 1.00 | CCR3 (0.84) | CCR3 | |
| SCHEMBL18840967 | 0.92 | CCR3 (1.00) | CCR3 | |
| SCHEMBL18841163 | 0.92 | CCR3 (1.00) | CCR3 | |
| SCHEMBL3881547 | 0.85 | CCR3 (0.73) | CCR3 | |
| SCHEMBL3881302 | 0.82 | CCR3 (0.67) | CCR3 | |
| SCHEMBL6217193 | 0.81 | CCR3 (0.71) | CCR3 | |
| SCHEMBL6217202 | 0.81 | CCR3 (0.71) | CCR3 | |
| SCHEMBL4578305 | 0.81 | CHRNB2 (0.69) | CCR3 | |
| SCHEMBL6217198 | 0.81 | CCR3 (0.71) | CCR3 | |
| SCHEMBL6217391 | 0.79 | CCR3 (1.00) | CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1161240-B1 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2005-08-17 | — | — | EP | claimed |
| US-20030114489-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | KO SOO S (US) | 2003-06-19 | — | — | US | claimed |
| US-6444686-B1 | FOR THE PREVENTION OF ASTHMA AND OTHER ALLERGIC DISEASES. | BRSITOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-03 | — | — | US | claimed |
| EP-1161240-A4 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | DU PONT PHARM CO (US) | 2002-04-03 | — | — | EP | claimed |
| EP-1161240-A1 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Du Pont Pharmaceuticals Company (US) | 2001-12-12 | — | — | EP | claimed |
| WO-2000035452-A1 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-06-22 | — | — | WO | claimed |
| EP-1161240-B1 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2005-08-17 | — | — | EP | disclosed |
| US-6897234-B2 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-05-24 | — | — | US | disclosed |
| US-20050096325-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | KO SOO S (US) | 2005-05-05 | — | — | US | disclosed |
| US-20030114489-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | KO SOO S (US) | 2003-06-19 | — | — | US | disclosed |
| US-6444686-B1 | FOR THE PREVENTION OF ASTHMA AND OTHER ALLERGIC DISEASES. | BRSITOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096325-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | CCR3, CCR1, ACKR3 | CCR3 1/4885 |
| US-20030114489-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | CCR3, CCR1, CCR10 | CCR3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.